Médicament comprenant un nouveau polypeptide
The cyclic peptide is prepared by oxidizing in an aqueous solution a linear peptide of the formula H-Cys-Tyr-Ile-Ala-Asp (NH2)-Cys-Pro-Leu-Gly-NH2 which is in turn prepared by reducing with an alkali peptide the correspondingly N- and S-protected nonapeptide. Tos - Cys(Bz) - Tyr - Ile - Ala - Asp(N...
Gespeichert in:
Hauptverfasser: | , |
---|---|
Format: | Patent |
Sprache: | fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The cyclic peptide is prepared by oxidizing in an aqueous solution a linear peptide of the formula H-Cys-Tyr-Ile-Ala-Asp (NH2)-Cys-Pro-Leu-Gly-NH2 which is in turn prepared by reducing with an alkali peptide the correspondingly N- and S-protected nonapeptide. Tos - Cys(Bz) - Tyr - Ile - Ala - Asp(NH2) - Cys (Bz) - Pro - Leu - GlyNH2 (where Tos= tosyl and Bz = benzyl) is prepared by condensing HAsp(NH2) - Cys(Bz) - Pro - Leu - GlyNH2 (from its CBO-derivative) with CBO-Ala-ONP to give CBO - Ala - Asp(NH2) - Cys(Bz) - Pro - Leu-Gly NH2, removing the CBO-group to give the free hexapeptamide and condensing it with Tos - Cys(Bz) - Tyr - Ile - ONP (where CBO= carbobenzyloxy and NP = p-nitrobenzyl). Pharmaceutical compositions comprise the cyclic peptide and an acceptable inert carrier and may be formulated for oral, parenteral or intranasal administration. |
---|